DL
Dave Licata
Chief Financial Officer, Chief Technology Officer, Director, Co-Founder
TORL BioTherapeuticsTherapeutic Areas
TORL BioTherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TORL-1-23 | CLDN6+ Solid Tumors (e.g., Platinum-Resistant Ovarian Cancer) | Phase 2 |
| TORL-4-500 | DLK1+ Solid Tumors | Phase 1 |
| TORL-5-700 | Undisclosed Hematologic Malignancy | Phase 1 |